abstract |
The invention relates to new compounds of the formula I Y– (CmH2m – CHR1) n – CO– (NH – CHR2 – CO) r – Z, where R1, R2, Y, Z, m, n and r have the meanings indicated in the claims. Compounds of formula I, as well as their solvates, inhibit the binding of fibrinogen, fibronectin and can be used for the treatment of thrombosis, apoplexy, myocardial infarction, inflammatory processes, atherosclerosis, and also as antitumor agents. |